Vyant Bio (NASDAQ:VYNT – Get Rating) and Aclarion (NASDAQ:ACON – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, profitability and risk. Institutional and Insider Ownership 28.7% of Vyant Bio shares are […]
Vyant Bio, Inc. (NASDAQ:VYNT – Get Rating) was the target of a significant increase in short interest in April. As of April 30th, there was short interest totalling 204,700 shares, an increase of 28.3% from the April 15th total of 159,500 shares. Based on an average daily volume of 69,200 shares, the short-interest ratio is […]
Platform and Poster Presentations on Vyant Bio’s Human First Drug Discovery Platform and Progress on CDKL5 Deficiency Disorder (CDD) CHERRY HILL, N.J.,.